Pharmacogenetic association of diabetes-associated genetic risk score with rapid progression of coronary artery calcification following treatment with HMG-CoA-reductase inhibitors —results of the Heinz Nixdorf Recall Study

HMG-CoA-Reductase inhibitors (HMGRIs) are currently the most widely used group of drugs in patients with coronary artery disease (CAD) and are given preemptively to patients with high levels of cholesterol, including those with diabetes mellitus (DM). However, intake of HMGRIs also increases the pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pechlivanis, Sonali, Jung, Dominik, Moebus, Susanne, Lehmann, Nils, Mahabadi, Amir A., Hoffmann, Per, Erbel, Raimund, Nöthen, Markus M., Bachmann, Hagen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298241/
https://www.ncbi.nlm.nih.gov/pubmed/34021798
http://dx.doi.org/10.1007/s00210-021-02100-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8298241/
https://www.ncbi.nlm.nih.gov/pubmed/34021798
http://dx.doi.org/10.1007/s00210-021-02100-7

Ejemplares similares